INVO Fertility Presents Five PRP Research Findings at 2026 Midwest Reproductive Symposium — INVO Fertility, Inc.

Event summary

INVO Fertility presented five poster abstracts on platelet-rich plasma (PRP) research at the 2026 Midwest Reproductive Symposium International (MRSi) in Chicago.
The studies evaluated ovarian and subendometrial PRP in patients with prior poor IVF outcomes, diminished ovarian response, and thin endometrial lining.
Key findings included improved ovarian response in younger patients, enhanced embryo development, and better pregnancy outcomes in select patients.
The research was conducted by Gretchen Collins, M.D., of Wisconsin Fertility Institute, an INVO Fertility clinic.
All findings are retrospective and require confirmation in larger, prospective investigations.

The big picture

INVO Fertility's presentation of PRP research at MRSi underscores its commitment to physician-led innovation and patient-centered care. The findings, if validated, could enhance treatment options for patients with poor IVF outcomes, potentially expanding access to assisted reproductive technology. The company's focus on supporting clinical research aligns with broader industry trends toward personalized and data-driven fertility treatments.

What we're watching

Clinical Validation: Whether the retrospective findings can be replicated in larger, prospective studies to validate PRP as an effective adjunct therapy.
Patient Selection: How INVO Fertility will refine patient selection criteria to optimize PRP treatment outcomes across different age groups and conditions.
Market Differentiation: The pace at which INVO Fertility can integrate PRP research into its clinic operations to differentiate itself in the competitive fertility treatment market.